FDA approves ataxia-telangiectasia drug; Alkermes reports ADHD data
RegulatoryapprovedAqneursaPositive
AI Analysis
Summary
The FDA approved Aqneursa, a rare genetic disease treatment for ataxia-telangiectasia developed by privately held IntraBio. The article also mentions data from Alkermes and news about other companies including Bristol Myers Squibb and Johnson & Johnson.
Outcome Details
FDA approved Aqneursa for ataxia-telangiectasia
Importance:8/10
Sentiment:
0.80
FDA approvalrare diseaseataxia-telangiectasiaregulatory
Read the original article
Published by Endpoints News on September 21, 2026 3:30 PM